September 29, 2022
(press release)
–
Metsä Tissue's, part of Metsä Group, renewed tissue paper machine at the Mänttä mill has moved from the trial run phase to continuous production. The renewed paper machine will be used to produce fresh fibre-based tissue paper products especially for the Finnish market. The upgrade will increase the production capacity of the tissue paper machine by 15 per cent, as well as improve product quality and energy and production efficiency. The renewal is an investment in increasing the production and improving the quality properties of Lambi, Serla and Katrin tissue paper products manufactured locally in Mänttä. The first products were trialled in June and the softness and strength of the paper have further improved. The new technology also enables tissue paper to be produced more energy-efficiently than before. The main machine supplier for the renewal was Valmet. "Tissue papers which are familiar to consumers’ everyday life are products that are important to the society’s security of supply. The renewal of the tissue machine enables us to increase production and at the same time take an important step towards fossil-free production. Development work on the renewal continues and I believe we will achieve the benefits we are aiming for and beyond. Our energy consumption will be reduced by around 15 per cent per tonne of paper produced, leading to lower carbon dioxide emissions in line with our sustainability targets. In addition to increased production capacity and better paper quality, also our occupational safety will improve," says Kari Karttunen, VP Production of the Mänttä mill. “We are proud to have the opportunity to continue our co-operation with Metsä Tissue in this important renewal project for Mänttä PM10. This is the third Advantage ViscoNip rebuild project that Valmet and Metsä Tissue have done together, and the cooperation has been very good in all projects. Valmet’s ViscoNip technology has major benefits related to improving product quality, reducing energy consumption and increase production capacity and is very well suited for rebuilds,” says Björn Magnus, Sales Director Rebuild & Single sales, Valmet. Metsä Tissue's strategy is to serve customers close to the markets with sustainably produced hygiene tissues and solutions. The main raw material used in tissue paper products is renewable northern wood, fresh fibre, which is pure, high quality and gives tissue paper good strength and softness properties. Metsä Tissue's Mänttä mill produces Serla, Lambi and Katrin tissue paper products and customers' own brands as well as SAGA baking paper products. The mill has three tissue machines, one greaseproof paper machine and 11 tissue converting lines. Photographs of Metsä Tissue's Mänttä mill: https://databank.metsagroup.com/l/vBX5XFj9g7Z2 For further information, please contact: Metsä Group Metsä Group is leading the way in advancing the bioeconomy. We invest in growth, bioproduct development and a fossil free future. The raw material for our products is renewable wood from sustainably managed northern forests. We focus on the growth sectors of the forest industry: wood supply and forest services, wood products, pulp, fresh fibre paperboards, as well as tissue and greaseproof papers. Metsä Group’s annual sales amount to approximately EUR 6 billion, and we have around 9,500 employees in 30 countries. Our international Group has its roots in the Finnish forests: our parent company is Metsäliitto Cooperative which is owned by nearly 100,000 forest owners.
Juha Laine, Senior Vice President, Communications, Metsä Group, tel. +358 10 465 4541
Kari Karttunen, Mänttä VP Production, Metsä Tissue, tel. +358 50 562 6635
Joanna Linnermo-Kumpuoja, Communications Manager, Metsä Tissue, tel. +358 40 555 5868 and joanna.linnermo-kumpuoja@metsagroup.com
www.metsagroup.com
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
